Menin inhibitors are novel targeted agents currently in clinical development for the treatment
of genetically defined subsets of acute leukemia. Menin has a tumor suppressor function in …

Epigenetic dysregulation is increasingly appreciated as a hallmark of cancer, including
disease initiation, maintenance and therapy resistance. As a result, there have been …

The identification of the multiple endocrine neoplasia type 1 (MEN1) gene in 1997 has
shown that germline heterozygous mutations in the MEN1 gene located on chromosome …

Ewing sarcoma (EwS) is characterized by EWSR1-ETS fusion transcription factors
converting polymorphic GGAA microsatellites (mSats) into potent neo-enhancers. Although …

Accumulating evidence shows that despite clonal origins tumors eventually become
complex communities comprised of phenotypically distinct cell subpopulations. This …

Menin‑mixed‑lineage leukemia (MLL) inhibitors have potential for use as therapeutic agents
for MLL‑rearranged leukemia. They are also effective against solid cancers, such as breast …

Acute myeloid leukemia (AML) is a clonal disorder of myeloid progenitors characterized by
the acquisition of chromosomal abnormalities, somatic mutations, and epigenetic changes …

The protein–protein interaction between menin and mixed-lineage leukemia 1 (MLL1) plays
an important role in development of acute leukemia with translocations of the MLL1 gene …

Recent studies in mouse models of cancer have shown that exercise improves tumor
vascular function, thereby improving chemotherapy delivery and efficacy. However, the …

EWS/FLI is the defining mutation of Ewing sarcoma. This oncogene drives malignant
transformation and progression and occurs in a genetic background characterized by few …